We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
51
Intellia Therapeutics
NTLA
$1.79B
$25.4M 0.31%
1,500,000
+1,164,000
+346% +$16.3M
WYNN icon
52
Wynn Resorts
WYNN
$9.43B
$25.3M 0.31%
261,065
+87,520
+50% +$9.03M
TMCI icon
53
Treace Medical Concepts
TMCI
$313M
$25.3M 0.31%
6,364,000
– –
AUTL
54
Autolus Therapeutics
AUTL
$596M
$24M 0.29%
15,000,000
-800,000
-5% -$1.26M
ARVN icon
55
Arvinas
ARVN
$614M
$23.2M 0.28%
2,796,000
+818,000
+41% +$7.63M
MGNX icon
56
MacroGenics
MGNX
$280M
$23.1M 0.28%
5,006,752
-1,005,248
-17% -$3.8M
ANRO icon
57
Alto Neuroscience
ANRO
$1.4B
$22.8M 0.28%
864,000
-48,000
-5% -$1.11M
TOST icon
58
Toast
TOST
$19.6B
$22.6M 0.28%
810,830
+233,359
+40% +$6.09M
PATH icon
59
UiPath
PATH
$7.87B
$21.7M 0.27%
2,000,000
+715,280
+56% +$7.64M
GRFS
60
Grifois
GRFS
$5.31B
$20.8M 0.25%
2,936,000
-52,000
-2% -$411K
CENTA icon
61
Central Garden & Pet Co Class A
CENTA
$2.26B
$20.8M 0.25%
536,000
+58,000
+12% +$2.02M
TSM icon
62
TSMC
TSM
$2.22T
$20.8M 0.25%
43,492
-17,762
-29% -$7.21M
S icon
63
SentinelOne
S
$6.92B
$20.5M 0.25%
1,205,661
-692,188
-36% -$10.6M
LEN icon
64
Lennar Class A
LEN
$20.1B
$20M 0.25%
221,444
+44,431
+25% +$3.97M
ISRG icon
65
Intuitive Surgical
ISRG
$130B
$19.4M 0.24%
48,804
-3,239
-6% -$1.42M
RH icon
66
RH
RH
$2.8B
$19.2M 0.24%
116,624
+68,624
+143% +$9.46M
ZETA icon
67
Zeta Global
ZETA
$7.87B
$19M 0.23%
965,273
+954,276
+8,678% +$17.7M
WDAY icon
68
Workday
WDAY
$47.2B
$18.9M 0.23%
154,030
+80,035
+108% +$10.1M
NBIS
69
Nebius Group N.V.
NBIS
$61.5B
$18.5M 0.23%
67,000
-41,000
-38% -$8.12M
INTC icon
70
Intel
INTC
$506B
$18M 0.22%
129,011
-94,984
-42% -$9.61M
BABA icon
71
Alibaba
BABA
$281B
$16.1M 0.2%
168,000
-36,000
-18% -$4.51M
ILMN icon
72
Illumina
ILMN
$33B
$16M 0.2%
+91,118
New +$13.3M
PBH icon
73
Prestige Consumer Healthcare
PBH
$2.48B
$15.9M 0.19%
+336,000
New +$17.3M
GSK icon
74
GSK
GSK
$100B
$15.7M 0.19%
300,000
+64,000
+27% +$3.38M
FWONK icon
75
Liberty Media Series C
FWONK
$23.9B
$15.7M 0.19%
+165,106
New +$14.8M
1 2
3
4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.